Lipocine Financial Statements From 2010 to 2026

LPCN Stock  USD 8.18  0.17  2.04%   
Lipocine's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Lipocine's valuation are provided below:
Gross Profit
4.3 M
Profit Margin
(1.27)
Market Capitalization
46.4 M
Enterprise Value Revenue
8.0718
Revenue
4.3 M
We have found one hundred twenty available fundamental ratios for Lipocine, which can be analyzed and compared to other ratios and to its peers in the industry. Self-guided Investors are advised to check Lipocine's last-minute fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 5th of February 2026, Market Cap is likely to drop to about 28.5 M. In addition to that, Enterprise Value is likely to drop to about 21.7 M

Lipocine Total Revenue

13.52 Million

Check Lipocine financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lipocine's main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 5.8 M or Total Revenue of 13.5 M, as well as many indicators such as Price To Sales Ratio of 2.54, Dividend Yield of 0.0 or PTB Ratio of 1.17. Lipocine financial statements analysis is a perfect complement when working with Lipocine Valuation or Volatility modules.
  
Build AI portfolio with Lipocine Stock
Check out the analysis of Lipocine Correlation against competitors.
To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.

Lipocine Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets29.4 M25.9 M25.2 M
Slightly volatile
Other Current Liabilities1.5 M1.1 M1.3 M
Pretty Stable
Total Current Liabilities3.3 M1.7 M2.7 M
Slightly volatile
Other Liabilities196.5 K206.9 K2.9 M
Slightly volatile
Accounts Payable296.8 K312.4 K607.5 K
Slightly volatile
Cash8.9 M5.6 M10 M
Pretty Stable
Cash And Short Term Investments26.4 M24.9 M22.7 M
Slightly volatile
Common Stock Total Equity10.7 K10.2 K4.6 K
Slightly volatile
Common Stock Shares Outstanding6.5 M6.2 M2.6 M
Slightly volatile
Liabilities And Stockholders Equity29.4 M25.9 M25.2 M
Slightly volatile
Other Current Assets620.4 K653.1 K1.2 M
Pretty Stable
Other Stockholder Equity154.2 M253.9 M139.5 M
Slightly volatile
Total Liabilities1.7 M1.7 M3.8 M
Pretty Stable
Total Current Assets28.5 M25.7 M24.5 M
Slightly volatile
Common Stock10.7 K10.2 K4.6 K
Slightly volatile
Property Plant Equipment124.4 K118.4 K72.8 K
Slightly volatile
Non Current Assets Total206.3 K217.2 K671.5 K
Pretty Stable
Capital Surpluse143.4 M251 M138.4 M
Slightly volatile
Property Plant And Equipment Gross1.7 M1.6 M588.6 K
Slightly volatile
Net Receivables103 K108.4 K329.2 K
Very volatile
Net Invested Capital27.2 M24.1 M22.5 M
Slightly volatile
Net Working Capital25.1 M23.9 M21.4 M
Slightly volatile
Short and Long Term Debt Total375 K394.8 K6.4 M
Slightly volatile
Long Term Debt Total4.3 M3.4 M5.5 M
Slightly volatile
Short and Long Term Debt2.5 M2.1 MM
Slightly volatile
Capital Stock7.6 K10.2 K4.9 K
Slightly volatile
Short Term Debt375 K394.8 K2.4 M
Slightly volatile
Current Deferred Revenue534.6 K288 K822.4 K
Slightly volatile
Non Current Liabilities OtherM1.2 M1.3 M
Slightly volatile

Lipocine Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative5.8 M5.8 MM
Slightly volatile
Other Operating Expenses14.6 M14.2 M12.6 M
Slightly volatile
Research Development9.1 M8.5 MM
Slightly volatile
Cost Of Revenue35.1 K37 K6.9 M
Slightly volatile
Total Operating Expenses10.7 M14.2 M9.5 M
Slightly volatile
Depreciation And Amortization38.8 K37 K26.1 K
Pretty Stable
Non Recurring582.9 K655.8 K715.8 K
Slightly volatile
Tax Provision426613609
Slightly volatile
Reconciled Depreciation49.6 K47.3 K25.6 K
Pretty Stable
Interest Income710.1 K1.3 M353.7 K
Slightly volatile

Lipocine Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
End Period Cash Flow9.8 M5.6 M11 M
Pretty Stable
Stock Based Compensation349.3 K367.7 K963.6 K
Pretty Stable
Begin Period Cash Flow4.1 M4.3 M10.5 M
Pretty Stable
Depreciation38.8 K37 K26.1 K
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables565 K750.5 K646.4 K
Slightly volatile
Capex To Depreciation3.931.977.6783
Pretty Stable
Payables Turnover7.968.3840.4977
Slightly volatile
Research And Ddevelopement To Revenue0.560.598.3236
Pretty Stable
Cash Per Share4.434.6618.9256
Slightly volatile
Days Payables Outstanding31.4745.0743.2439
Slightly volatile
Current Ratio12.5316.9711.3654
Very volatile
Graham Number0.30.330.3653
Slightly volatile
Debt To Equity0.05540.05830.6827
Slightly volatile
Capex Per Share0.03210.01940.0245
Slightly volatile
Average Receivables94.3 K99.3 K218 K
Very volatile
Interest Debt Per Share0.00590.00624.7998
Slightly volatile
Debt To Assets0.04810.05060.311
Slightly volatile
Days Of Payables Outstanding31.4745.0743.2439
Slightly volatile
Long Term Debt To Capitalization0.140.150.3011
Slightly volatile
Total Debt To Capitalization0.05270.05550.3405
Slightly volatile
Debt Equity Ratio0.05540.05830.6827
Slightly volatile
Quick Ratio12.5316.9711.3654
Very volatile
Net Income Per E B T1.091.061.0002
Slightly volatile
Cash Ratio6.364.725.5852
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.131.231.0618
Pretty Stable
Debt Ratio0.04810.05060.311
Slightly volatile

Lipocine Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap28.5 M30 M56.4 M
Slightly volatile
Enterprise Value21.7 M22.8 M39.9 M
Pretty Stable

Lipocine Fundamental Market Drivers

Lipocine Upcoming Events

8th of March 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
8th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Lipocine Financial Statements

Lipocine investors utilize fundamental indicators, such as revenue or net income, to predict how Lipocine Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue288 K534.6 K
Total Revenue12.9 M13.5 M
Cost Of Revenue37 K35.1 K
Stock Based Compensation To Revenue 0.04  0.04 
Sales General And Administrative To Revenue 0.51  0.49 
Research And Ddevelopement To Revenue 0.59  0.56 
Capex To Revenue 0.01  0.01 
Revenue Per Share 2.41  2.29 
Ebit Per Revenue(0.09)(0.10)

Pair Trading with Lipocine

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lipocine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lipocine will appreciate offsetting losses from the drop in the long position's value.

Moving together with Lipocine Stock

  0.75JNJ Johnson JohnsonPairCorr

Moving against Lipocine Stock

  0.9HPQ HP Inc Aggressive PushPairCorr
  0.67MSFT MicrosoftPairCorr
  0.45BRK-A Berkshire HathawayPairCorr
  0.43VLCN Volcon Inc Symbol ChangePairCorr
  0.42PSGTF PT Semen IndonesiaPairCorr
The ability to find closely correlated positions to Lipocine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lipocine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lipocine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lipocine to buy it.
The correlation of Lipocine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lipocine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lipocine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lipocine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Lipocine offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lipocine's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lipocine Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lipocine Stock:
Check out the analysis of Lipocine Correlation against competitors.
To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.
You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Will Pharmaceuticals sector continue expanding? Could Lipocine diversify its offerings? Factors like these will boost the valuation of Lipocine. Expected growth trajectory for Lipocine significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Lipocine data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(1.02)
Revenue Per Share
0.806
Quarterly Revenue Growth
5.954
Return On Assets
(0.21)
Return On Equity
(0.33)
Understanding Lipocine requires distinguishing between market price and book value, where the latter reflects Lipocine's accounting equity. The concept of intrinsic value - what Lipocine's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Lipocine's price substantially above or below its fundamental value.
Understanding that Lipocine's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Lipocine represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Lipocine's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.